Literature DB >> 31558664

Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features?

Valentina F I Sangiorgio1,2, Julia T Geyer3, Elizabeth Margolskee3, Mustafa Al-Kawaaz3, Susan Mathew3, Wayne Tam3, Attilio Orazi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31558664      PMCID： PMC7271604          DOI： 10.3324/haematol.2019.227686

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Authors:  Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.

Authors:  W Ingram; N C Lea; J Cervera; U Germing; P Fenaux; B Cassinat; J J Kiladjian; J Varkonyi; P Antunovic; N B Westwood; M J Arno; A Mohamedali; J Gaken; T Kontou; B H Czepulkowski; N A Twine; J Tamaska; J Csomer; S Benedek; N Gattermann; E Zipperer; A Giagounidis; Z Garcia-Casado; G Sanz; G J Mufti
Journal:  Leukemia       Date:  2006-04-13       Impact factor: 11.528

3.  Cytogenetic findings in untreated patients with essential thrombocythemia.

Authors:  Anna D Panani
Journal:  In Vivo       Date:  2006 May-Jun       Impact factor: 2.155

4.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

Authors:  Austin G Kulasekararaj; Alexander E Smith; Syed A Mian; Azim M Mohamedali; Pramila Krishnamurthy; Nicholas C Lea; Joop Gäken; Coralie Pennaneach; Robin Ireland; Barbara Czepulkowski; Sabine Pomplun; Judith C Marsh; Ghulam J Mufti
Journal:  Br J Haematol       Date:  2013-01-09       Impact factor: 6.998

5.  Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

Authors:  Mar Mallo; Mónica Del Rey; Mariam Ibáñez; M José Calasanz; Leonor Arenillas; M José Larráyoz; Carmen Pedro; Andrés Jerez; Jaroslaw Maciejewski; Dolors Costa; Meritxell Nomdedeu; María Diez-Campelo; Eva Lumbreras; Teresa González-Martínez; Isabel Marugán; Esperanza Such; José Cervera; Juan C Cigudosa; Sara Alvarez; Lourdes Florensa; Jesús M Hernández; Francesc Solé
Journal:  Br J Haematol       Date:  2013-04-25       Impact factor: 6.998

6.  Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.

Authors:  Rafael Santana-Davila; Ayalew Tefferi; Shernan G Holtan; Rhett P Ketterling; Gordon W Dewald; Ryan A Knudson; David P Steensma; Dong Chen; James D Hoyer; Curtis A Hanson
Journal:  Leuk Res       Date:  2008-06-09       Impact factor: 3.156

7.  WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Authors:  M M Patnaik; T L Lasho; C M Finke; N Gangat; D Caramazza; S G Holtan; A Pardanani; R A Knudson; R P Ketterling; D Chen; J D Hoyer; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2010-05-20       Impact factor: 12.883

8.  Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes.

Authors:  Manja Meggendorfer; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

Review 9.  Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Authors:  Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Emiliano Fabiani; Maria Teresa Voso; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena
Journal:  Onco Targets Ther       Date:  2014-06-13       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.